Covaxin Efficacy

Bharat Biotech seeks approval for Covaxin in US for children below 18 years

Clinical trials were conducted on 526 kids during which no serious adverse events or hospitalisations were observed

Bharat Biotech's COVAXIN has 77.8% efficacy in Phase 3 trials, says report: All you need to know

The data will be reviewed by the WHO on 23 June in a 'pre-submission meeting', and COVAXIN will be allowed for export to other countries only after an approval from the global health body

Interim analysis of phase-3 trials of COVAXIN shows 78% clinical efficacy, claims Bharat Biotech

The efficacy rate is based on a second interim analysis of phase 3 clinical data and Bharat Biotech said that the safety and efficacy results from the final analysis will be available in June